彩民宝典

Leslie Leinwand is a Molecular, Cellular, and Developmental Biology (MCDB) Distinguished Professor and the Chief Scientific Officer of the BioFrontiers Institute at the 彩民宝典. She was recruited to be Chair of MCDB in 1995. She received her Bachelor鈥檚 degree from Cornell University, her PhD from Yale University, and did post-doctoral training at Rockefeller University. She joined the faculty at Albert Einstein College of Medicine in New York in 1981 and remained there until moving to Colorado in 1995. She co-founded Myogen, Inc. which was sold to Gilead Pharmaceuticals. She was also a co-founder of Hiberna, Inc, and more recently of MyoKardia, Inc., a publicly-traded company founded to develop therapeutics for inherited cardiomyopathies. She is a Fellow of the AAAS, former MERIT Awardee of the NIH, Established Investigator of the American Heart Association, and was recently elected to the American Academy of Arts and Sciences and the National Academy of Inventors. The interests of Dr. Leinwand鈥檚 laboratory are the genetics and molecular physiology of inherited diseases of the heart and how gender and diet modify the heart. The study of these diseases has required multidisciplinary approaches, involving molecular biology, mouse genetics, mouse cardiac physiology, and the analysis of human tissues. Her teaching was recognized by funding from the Howard Hughes Medical Institute鈥檚 Professor Program.